Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO

A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer.

STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO

We haven't written up this one. STAT News has the full story — the link below goes straight to it.

Read the original at statnews.com →

More in Health & Medicine

More from Monday 26 October →